Jounce Therapeutics, Inc.
JNCE · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $82,000 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $82,000 | $0 | $0 | $0 |
| % Margin | 100% | – | – | – |
| R&D Expenses | $23,203 | $23,752 | $26,203 | $30,115 |
| G&A Expenses | $8,458 | $7,653 | $7,511 | $7,347 |
| SG&A Expenses | $8,458 | $7,653 | $7,511 | $7,347 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $213 | $96 |
| Operating Expenses | $31,661 | $31,405 | $33,714 | $37,462 |
| Operating Income | $50,339 | -$31,405 | -$33,714 | -$37,462 |
| % Margin | 61.4% | – | – | – |
| Other Income/Exp. Net | -$51,505 | $412 | $213 | $96 |
| Pre-Tax Income | $51,076 | -$30,993 | -$33,501 | -$37,366 |
| Tax Expense | $117 | $5 | $12 | $1 |
| Net Income | $50,959 | -$30,998 | -$33,513 | -$37,367 |
| % Margin | 62.1% | – | – | – |
| EPS | 0.99 | -0.6 | -0.65 | -0.72 |
| % Growth | 265% | 7.7% | 9.7% | – |
| EPS Diluted | 0.99 | -0.6 | -0.65 | -0.72 |
| Weighted Avg Shares Out | 51,676 | 51,694 | 51,678 | 51,638 |
| Weighted Avg Shares Out Dil | 51,676 | 51,694 | 51,678 | 51,638 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $442 | $495 | $560 | $590 |
| EBITDA | $50,781 | -$30,910 | -$33,154 | -$36,872 |
| % Margin | 61.9% | – | – | – |